GlassScriptPhysician profile
Shawn Shambaugh
NPI 1659360253
$34,019.17
in general payments reported to CMS, 2019-2025
80 companies · $6,000 in 2025
The $6,000 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,569 · 2020: $3,489 · 2021: $3,133 · 2022: $3,984 · 2023: $5,684 · 2024: $6,160 · 2025: $6,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Consulting Fee: $1,050 · Education: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,234.28 |
| Consulting Fee | $1,050.00 |
| Education | $560.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,970.46 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Exelixis INC. | $2,384.07 | 2019-2025 | Cabometyx |
| Daiichi Sankyo INC. | $2,249.85 | 2019-2025 | Injectafer, Enhertu, Vanflyta |
| Janssen Biotech, INC. | $1,828.09 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Glaxosmithkline, LLC. | $1,618.40 | 2019-2025 | Ojjaara, Zejula, Jemperli |
| Pfizer INC. | $1,547.14 | 2019-2025 | |
| Seagen INC. | $1,322.10 | 2019-2023 | Adcetris, Tukysa |
| Genzyme Corporation | $1,308.43 | 2019-2025 | |
| Amgen INC. | $1,307.96 | 2019-2023 | Kyprolis, Blincyto, Xgeva |
| E.R. Squibb & Sons, L.L.C. | $990.26 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Genentech USA, INC. | $969.28 | 2019-2025 | Polivy, Tecentriq, Phesgo |
| Pharmacyclics LLC, An Abbvie Company | $961.98 | 2019-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $957.29 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Novartis Pharmaceuticals Corporation | $888.97 | 2019-2025 | |
| Astellas Pharma US INC | $782.29 | 2019-2025 | Xospata, Vyloy, Xtandi |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $763.34 | 2019-2025 | Fruzaqla, Alunbrig, Iclusig |
| Regeneron Healthcare Solutions, INC. | $713.25 | 2019-2025 | Libtayo |
| Sobi, INC | $669.15 | 2023-2025 | |
| Eisai INC. | $572.15 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $552.88 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Incyte Corporation | $550.03 | 2019-2025 | Jakafi, Niktimvo, Monjuvi |
| Amag Pharmaceuticals, INC. | $427.36 | 2019-2022 | |
| Lilly USA, LLC | $422.43 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $406.73 | 2021-2025 | Trodelvy |
| Stemline Therapeutics INC. | $386.72 | 2019-2025 | Orserdu, Elzonris |
| Tesaro, INC. | $360.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $357.33 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $344.26 | 2019-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $338.55 | 2019-2025 | Zepzelca |
| Bayer Healthcare Pharmaceuticals INC. | $300.72 | 2019-2024 | |
| Blueprint Medicines Corporation | $285.36 | 2023-2025 | Ayvakit |
| Sun Pharmaceutical Industries INC. | $282.63 | 2021-2024 | Yonsa |
| Puma Biotechnology, INC. | $265.17 | 2019-2025 | |
| Array Biopharma INC | $256.52 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Abbvie INC. | $255.67 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $255.41 | 2019-2021 | |
| Octapharma USA, INC. | $245.52 | 2019-2021 | |
| Pharmaessentia USA Corporation | $243.14 | 2024-2025 | Besremi |
| Novocure Gmbh | $200.00 | 2022 | |
| Emd Serono, INC. | $190.19 | 2019-2025 | Bavencio, Tepmetko |
| Adc Therapeutics America, INC. | $154.17 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $151.83 | 2021-2023 | Xpovio |
| Genmab U.S., INC. | $150.76 | 2024-2025 | Epkinly |
| Secura Bio, INC. | $123.43 | 2021 | |
| Blue Earth Diagnostics | $116.11 | 2019-2022 | |
| Comsort, INC | $100.00 | 2019 | |
| Spectrum Pharmaceuticals INC. | $99.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2019 | |
| Agios Pharmaceuticals, INC. | $88.55 | 2024-2025 | Pyrukynd |
| Beone Medicines USA, INC. | $88.48 | 2025 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $84.04 | 2023-2024 | Rezlidhia, Tavalisse |
| Morphosys, US INC. | $80.10 | 2021-2023 | Monjuvi |
| Dova Pharmaceuticals | $80.00 | 2020-2021 | |
| Beigene USA, INC. | $77.78 | 2023-2025 | Brukinsa |
| Caris Mpi, INC. | $77.56 | 2025 | Mi Cancer Seek |
| Deciphera Pharmaceuticals INC. | $66.14 | 2023-2025 | Qinlock, Romvimza |
| Apellis Pharmaceuticals, INC. | $60.93 | 2023 | Empaveli |
| Pharmacosmos Therapeutics INC. | $59.71 | 2022-2025 | Monoferric |
| Clovis Oncology, INC. | $53.54 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $45.92 | 2023-2024 | Sylvant |
| Myriad Genetic Laboratories, INC. | $43.10 | 2023-2024 | Myrisk, Prolaris |
| Kyowa Kirin, INC. | $37.29 | 2022 | |
| Syndax Pharmaceuticals, INC. | $32.82 | 2025 | |
| Aveo Pharmaceuticals, INC. | $31.54 | 2022 | |
| Geron Corporation | $29.65 | 2025 | Rytelo |
| Fennec Pharmaceuticals, INC. | $25.31 | 2025 | Fyarro |
| Mirati Therapeutics, INC. | $20.85 | 2023 | Krazati |
| Aurobindo Pharma USA, INC. | $19.61 | 2019 | |
| Menarini Silicon Biosystems, INC. | $18.56 | 2025 | Cellsearch |
| Eusa Pharma (US) LLC | $18.55 | 2019 | |
| Accord Healthcare, INC. | $18.10 | 2025 | |
| Epizyme, INC. | $17.86 | 2020 | |
| Biogen, INC. | $17.86 | 2021 | |
| Myovant Sciences INC. | $17.10 | 2021 | |
| Aadi Bioscience, INC. | $16.70 | 2023 | Fyarro |
| Coherus Oncology, INC. | $15.92 | 2023 | |
| Heron Therapeutics, INC. | $15.55 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.36 | 2025 | Danziten |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.52 | 2025 | |
| Janssen Pharmaceuticals, INC | $4.43 | 2024 | Xarelto |
Drugs and devices associated with these payments
Cabometyx $1,375Imfinzi $1,096Enhertu $766Ojjaara $576Injectafer $571Imbruvica $442Calquence $437Doptelet $420Zejula $371Reblozyl $365Libtayo $365Lenvima $359Verzenio $357Tukysa $348Darzalex $324Pluvicto $318Jemperli $316Ibrance $309Tecvayli $305Epkinly $303Orserdu $301Adcetris $292Ayvakit $285Braftovi $255Lynparza $254Vonjo $249Fruzaqla $248Xtandi $246Besremi $243Opdivo $242Keytruda $241Trodelvy $234Xospata $232Erleada $225Tagrisso $218Padcev $216Mektovi $211Carvykti $210Jaypirca $200Enjaymo $199Cablivi $199Yonsa $199Scemblix $195Polivy $194Elrexfio $193Inlyta $189Lutathera $183Talvey $182Vanflyta $171Rybrevant $168Brukinsa $166Alunbrig $157Jakafi $157Odomzo $153Opdualag $141Ultomiris $140Talzenna $139Lorbrena $138Zepzelca $114Vyloy $110Tecentriq $97.17Phesgo $93.49Pyrukynd $88.55Venclexta $86.50Tavalisse $84.04Rezlidhia $84.04Niktimvo $81.59Kyprolis $77.87Mi Cancer Seek $77.56Xalkori $77.31Bavencio $75.05Blenrep $74.94Nerlynx $72.25Sarclisa $71.70Xpovio $66.67Qinlock $66.14Monjuvi $62.05Shingrix $59.07Pomalyst $58.76Wayrilz $55.04Bosulif $53.43Iclusig $51.85Blincyto $50.93Sylvant $45.92Zynlonta $45.27Lunsumio $44.58Columvi $44.58Akeega $44.31Balversa $44.31Fyarro $42.01Datroway $41.71Retevmo $41.57Stivarga $38.92Monoferric $38.47Xofigo $37.23Nubeqa $37.23Xgeva $31.28Elitek $30.27Rytelo $29.65Ziihera $28.75
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Shambaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.